Analysis of efficacy and safety of new oral anticoagulants in the treatment of elderly patients with non-valvular atrial fibrillation / 中国基层医药

ABSTRACT

Objective:To investigate the efficacy and safety of new oral anticoagulants in the treatment of elderly patients with non-valvular atrial fibrillation.Methods:From March 2016 to September 2018, 176 elderly patients with non-valvular atrial fibrillation admitted to Lyucheng Cardiovascular Hospital of Zhejiang Province were selected and divided into warfarin group(56 cases), dabiga group(64 cases) and rivaroxaban group(56 cases) according to the treatment conditions.All three groups were treated for 6 months.The incidence of embolism and bleeding events, the changes of blood sugar and liver, kidney function before and after treatment in three groups were compared.Results:The incidence rates of thromboembolism in the warfarin group, dabiga group and rivaroxaban group were 7.14%(4/56), 1.56%(1/64), 3.57%(2/56), respectively, there was no statistically significant difference among the three groups( U=2.457, P>0.05). The incidences of bleeding in the warfarin group, dabiga group and rivaroxaban group were 16.07%(9/56), 3.13%(2/64), 1.79%(1/56), respectively, there was statistically significant difference among the three groups( U=11.090, P<0.05), which in the warfarin group was significantly higher than that in the dabicarbonate group and rivaroxaban group(χ 2=6.012, 7.028, all P<0.05). There were no statistically significant differences in blood sugar, lipid, liver and kidney function among the three groups before and after treatment(all P>0.05). Conclusion:Compared with warfarin, the new oral anticoagulant dapigatron ester and rivaroxaban have similar effects in preventing stroke and thromboembolism in elderly patients with non-valvular atrial fibrillation, while the risk of bleeding events during the administration of dapigatron ester and rivaroxaban is lower, suggesting that the new oral anticoagulant is effective in the treatment of stroke and thromboembolism in elderly patients with non-valvular atrial fibrillation.The therapy has high efficacy and safety, which is worthy of clinical promotion.